Adjuvant cancer therapy company in Southern Europe for sale

Company for sale

• Size: Small
• Revenue: < 3 million EUR
• Location: Southern Europe
• Suited for: Financial and strategic investors
• CFIE PHS179

Overview of adjuvant cancer therapy company in Southern Europe for sale

Currently, a Southern European company specializing in cancer research and development (R&D) is available for sale. Predominately, the company’s primary focus is on biomedical research. In particular, geared towards improving the quality of life for cancer patients. Equally important, they explore innovative solutions for various diseases. Notably, they have a strong emphasis on patent development and market-ready products. Moreover, the company operates through its projects and collaborations with public research centers.

Profile of adjuvant cancer therapy company in Southern Europe for sale

Chiefly, the company is a dedicated research development and innovation (R&D&I) entity. Above all, it is committed to advancing scientific research and fostering collaborations with public institutions and research centers. Essentially, their mission revolves around enhancing patient well-being through the creation of novel therapies, drugs, and products. Furthermore, they are situated in Southern Europe where the company benefits from a well-equipped facility. Altogether, the premises support comprehensive scientific endeavors and innovation initiatives.

Activities and products of adjuvant cancer therapy company in Southern Europe for sale

1. Nanoparticles project: Collaborating with renowned institutions, the company is developing nanoparticles loaded with active ingredients to reduce toxicity in various pathologies associated with cancer treatments and other diseases.
2. Exosomes project: Researching exosomes of plant origin, the company aims to unlock the therapeutic and cosmetic potential of these novel ingredients, targeting a wide range of pathologies.
3. Drug development: Partnering with research centers, the company is developing innovative drugs to treat specific conditions such as allodynia, focusing on improving patient outcomes and quality of life.
4. Olive leaf research: Investigating components of olive leaves with antimicrobial and antioxidant properties, the company has discovered promising active ingredients with potential applications in healthcare products.
5. Quick tests project: Collaborating with experts in nanoscience, the company is working on developing rapid virus detection tests, aiming to provide efficient and reliable solutions for virus detection.
6. Product repositioning: The company is also engaged in repositioning existing active ingredients to create products with new indications, addressing market needs, and expanding its product offerings.

Highlights of adjuvant cancer therapy company in Southern Europe for sale

• Specialization in cancer research and dedication to enhancing patient outcomes
• Collaborative partnerships with renowned research institutions
• Diverse portfolio of R&D projects encompassing nanoparticles, exosomes, drugs, olive leaf research, rapid virus tests, and product repositioning
• Well-equipped facility, supporting comprehensive scientific research and development efforts
• Commitment to innovation, quality, and adherence to industry standards in biomedical research and product development

More information on this adjuvant cancer therapy company in Southern Europe for sale

Please get in touch if you are interested in learning more about this adjuvant cancer therapy company in Southern Europe for sale. For more pharma companies for sale please visit the section pharma companies for sale. For other pharma buyers, please visit the section pharma companies wanted. If you are instead interested in pharma companies for sale, please visit the pharma companies for sale section. For pharma buyers, please visit the section pharma companies wanted.